Key result
Troponin T elevation below functional sensitivity predicts ~360% higher 6-month death and AMI risk.
Why the study?
Does adopting a lower troponin T diagnostic cut-off at the 99th percentile, below the functional sensitivity of the assay, improve prognostic stratification for adverse events in patients with suspected ACS?
Cohort (n=804)
No
Does adopting a lower troponin T diagnostic cut-off at the 99th percentile, below the functional sensitivity of the assay, improve prognostic stratification for adverse events in patients with suspected ACS?
Adopting a lower troponin T cut-off at the 99th percentile, even when below the assay's functional sensitivity (CV ≤10%), identifies patients at significantly increased risk of death, AMI, and MACE at 6 months.
Answers are grounded in this paper and cite their sources.
May support lower troponin T thresholds for risk stratification in suspected ACS; leaves open need for prospective validation before practice change.
BACKGROUND: Recent consensus guidelines state that acute myocardial infarction (AMI) may be diagnosed in the context of a troponin rise above the 99th percentile of the upper reference limit (URL) with the optimal imprecision of the assay (coefficient of variation, CV) being <or=10%. However, at the 99th percentile, modern assays do not have a CV <or=10%. Objective The authors compared the prognostic implications of placing the diagnostic troponin cut-off at the 99th percentile and at the lowest concentration with a CV <or=10% (functional sensitivity). METHODS: The authors prospectively recruited 804 patients presenting to the Emergency Department of a university-affiliated teaching hospital with suspected ACS. All patients underwent 12 h troponin T testing and were followed up by telephone and chart review. Outcomes Death or AMI (excluding the index event) and the occurrence of major adverse cardiac events (MACEs) within 6 months. RESULTS: Troponin T elevation below the functional sensitivity predicted the risk of death and AMI (adjusted OR 4.6, p=0.039) and MACE (adjusted OR 11.10, p<0.0001) independently of the Thrombolysis in Myocardial Infarction risk score and creatinine levels. Utilising the 99th percentile cut-off, an extra 17 MACEs could be predicted per 1000 patients treated at a cost of identifying 11 patients who would not have developed an event. CONCLUSIONS: The results suggest that adopting the lower troponin cut-off would reduce the proportion of 'false negatives' (patients with negative troponin who develop MACE) from 9.6% to 8.9%. Whether this reduction in 'false negatives' justifies the increase in 'false positives' warrants further investigation and discussion.
No takes yet. Share an insight, caveat, or question.
Body et al. (2010) conducted a cohort in Suspected ACS (n=804). Troponin T elevation below the functional sensitivity vs. Negative troponin was evaluated on Death or AMI (excluding the index event) (OR 4.6, p=0.039). Troponin T elevation below the functional sensitivity independently predicted the risk of death and AMI and major cardiovascular events at 6 months.
Synapse has enriched 10 related papers. Consider them for comparative context: